Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Coronary artery stent" patented technology

Method for reducing incidence of in-stent restenosis and special stainless steel material thereof

ActiveCN102618796AReduce the incidence of restenosisReduce restenosis functionStentsSurgeryCoronary arteriesStent implantation
The invention relates to the field of coronary stents, specifically to a method for reducing the incidence of in-stent restenosis and its special stainless steel material. The method of the invention adds a proper amount of copper element (2.0-6.0% by weight) into the common clinical coronary stent material 316L stainless steel, and conducts special heat treatment so as to make the copper separated in a copper-rich phase out of the stainless steel substrate. The stent is enabled to continuously release trace amounts of copper ions in a clinical environment, and the coronary stent is endowed with an anti-restenotic function, thus effectively reducing the incidence of restenosis after stent implantation. With a unique function of reducing the in-stent restenosis phenomenon caused by stent implantation into a coronary artery, the 316L type copper-containing stainless steel of the invention is conducive to solve clinical problems such as high incidence of in-stent restenosis after implantation of existing stainless steel coronary stents, and can be applied in coronary stents and other clinical medicine fields, thus providing a new idea and material basis for development and application of coronary stents.
Owner:蔻沛斯蒂(浙江)医疗器械有限公司

Drug-eluting coronary artery stent and method for preparing same

InactiveCN101513540AGood biocompatibilityReduced burst release phenomenonStentsSurgeryMicro arc oxidationMicrosphere
The invention provides a drug-eluting coronary artery stent and a method for preparing the same. The method comprises the following steps: providing a basal body for the coronary artery stent; providing a micro arc oxidation treatment device comprising an electrolyte tank; adding an electrolyte into the electrolyte tank and stirring the electrolyte evenly, wherein the formulation of the electrolyte comprises that calcium acetate (CH3COO)2Ca.H2O of which the concentration is between 0.2 and 0.6 mol per liter and sodium dihydrogen phosphate NaH2PO4 of which the concentration is between 0.02 and 0.06 mol per liter are added to 400 milliliters of distilled water respectively; and putting the basal body of the coronary artery stent into the electrolyte, starting the micro arc oxidation treatment device to run for 1 to 12 minutes to obtain the basal body of the coronary artery stent, and then assembling the basal body of the coronary artery stent with microspheres for encapsulating drugs so as to obtain the drug-eluting coronary artery stent. While the drug-eluting coronary artery stent slowly releases the drugs, the drug-eluting coronary artery stent promotes the complete blood vessel endothelialization on the surface of the implanted coronary artery stent for endothelial tissues of normal coronary artery blood vessels to grow on the surface of the implanted stent.
Owner:D PULSE MEDICAL BEIJING CO LTD

Method for reducing incidence of in-stent restenosis and special stainless steel material thereof

ActiveCN102618796BReduce the incidence of restenosisReduce restenosis functionStentsSurgeryCoronary arteriesStent implantation
The invention relates to the field of coronary stents, specifically to a method for reducing the incidence of in-stent restenosis and its special stainless steel material. The method of the invention adds a proper amount of copper element (2.0-6.0% by weight) into the common clinical coronary stent material 316L stainless steel, and conducts special heat treatment so as to make the copper separated in a copper-rich phase out of the stainless steel substrate. The stent is enabled to continuously release trace amounts of copper ions in a clinical environment, and the coronary stent is endowed with an anti-restenotic function, thus effectively reducing the incidence of restenosis after stent implantation. With a unique function of reducing the in-stent restenosis phenomenon caused by stent implantation into a coronary artery, the 316L type copper-containing stainless steel of the invention is conducive to solve clinical problems such as high incidence of in-stent restenosis after implantation of existing stainless steel coronary stents, and can be applied in coronary stents and other clinical medicine fields, thus providing a new idea and material basis for development and application of coronary stents.
Owner:蔻沛斯蒂(浙江)医疗器械有限公司

Medicament sustained-release coating

The invention relates to a medicament sustained-release coating. A double-medicament sustained-release coating consists of medicaments and a polymer carrier, wherein the medicaments are used for inhibiting thrombosis and hyperblastosis. The double-medicament sustained-release coating is characterized in that: an external medicament sustained-release coating is applied on the surface of a coronary artery stent; an internal medicament sustained-release coating is placed in a micropore storage groove of the coronary artery stent; the external medicament sustained-release coating is applied on the surface of the coronary artery stent by an ultrasonic atomizing spraying process; the polymer carrier is polylactic acid-glycolic acid (PLGA); and the weight ratio of the polymer carrier to the medicaments is 3:1-10:1. The double-medicament sustained-release coating has the advantages of: 1, guaranteeing that the medicaments can adopt different release sequences and different duration time according to different pathogenesis; 2, maintaining stable blood medicament effective concentration so as to inhibit restenosis of blood vessels and thrombosis; 3, inhibiting proliferation of smooth muscles, reducing thrombosis, promoting healing and improving endothelial function; and 4, greatly improving control of medicament release rate and directivity.
Owner:TIANJIN TIANXIANG GLASSWARE

Method for manufacturing heart structure through rollover process of 3D printing technology

The invention discloses a method for manufacturing a heart structure by using a rollover process of a 3D printing technology, and aims to solve the problems that only the internal structure of the heart can be displayed and a later heart model rollover technology is lacked in the prior art, so that a heart practice medical teaching aid is manufactured to meet various surgical operations of the internal structure of the heart and coronary artery stent and bridging technology practice; and human heart structure real data are obtained through heart structure medical imaging and data digitization, heart three-dimensional data structure data are subjected to 3D printing to manufacture a heart model or a heart template, the toughness and thickness of heart valves and the shape and thickness of coronary arteries are achieved. According to the heart silica gel filling, all reserved template gaps can be uniformly filled through negative pressure attraction silica gel according to product requirements, compared with a traditional manufacturing method, the rate of finished products is high, and the internal structure shape of the heart is closer to the real heart structure of a human body; and the artificial heart can be used for simulating and practicing clinical operation skills such as heart cutting, sewing, plugging, coronary artery stenting and bridging.
Owner:东莞雀鹏医疗信息科技有限公司

Pressure-difference monitoring device based on heart coronary artery stent and method thereof

The invention relates to a pressure-difference monitoring device based on a heart coronary artery stent and a method thereof. The pressure-difference monitoring device based on the heart coronary artery stent and the method thereof are characterized in that the monitoring device comprises a heart coronary artery stent, two integrated circuits and an external processing device; the heart coronary artery stent is used as an antenna, and the two integrated circuits are fixedly arranged at an inlet and an outlet of a blood vessel of the heart coronary artery stent respectively; all the integrated circuits comprise energy supplying modules, pressure sensors, storages, data processors and first radio-frequency receiving and dispatching modules, and all the energy supplying modules are used for supplying power to the integrated circuits; the pressure sensors transmit detected blood pressure signals to the data processors through the storages, the blood pressure signals are converted into digital signals through the data processors, and the first radio-frequency receiving and dispatching modules transmit the digital signals to the external processing device through the heart coronary artery stent. The pressure-difference monitoring device based on the heart coronary artery stent and the method thereof can be widely applied to state monitoring of cardiovascular diseases.
Owner:任勇

Coronary artery stent implantation operation image operation platform

The invention discloses a coronary artery stent implantation surgery image operation platform which comprises a supporting table, a rotating groove is formed in the supporting table, a rotating rod is rotationally connected to the rotating groove, a supporting rod is fixedly installed at the upper end of the rotating rod, a lifting groove is formed in the supporting rod, a lifting rod is slidably connected into the lifting groove, and a rotating shaft is arranged in the lifting rod. And moving blocks are fixedly mounted on the left side and the right side of the lifting rod correspondingly, moving grooves are formed in the left side and the right side of the lifting groove correspondingly, the two moving grooves are matched with the two moving blocks correspondingly, and sliding rods are fixedly mounted on the two moving blocks correspondingly. The medical image display device has the advantages that doctors standing at different positions can clearly check images in the body of a patient, so that the success rate of an operation can be improved to a certain extent, the mounting height and the vertical angle of the display screen can be adjusted according to needs, the doctors can better clearly check the images on the display screen, and the operation efficiency is improved. And the application range is wider.
Owner:PINGMEI SHENMA MEDICAL GRP GENERAL HOSPITAL

Device and method for safely positioning a coronary stent in the coronary arteries

InactiveCN110709035AStentsSurgeryCoronary arteriesVisceral artery
The invention is intended for use in medicine and enables maximally precise, quick and safe positioning of a coronary stent in the case of uncomplicated and complicated anatomical injuries of the coronary vascular bed, and also when stenting renal and visceral arteries. The claimed device consists of a body with a tail portion, a wheel for rotating a screw, a screw, a slider with threaded elementsand a scale for identifying the position of the slider and a resilient tensioning member with elastic locking members disposed thereon, a wedge piece consisting of two elements, a spring and a lock button, arranged inside the body. When preparing the device for use, the coronary stent is first inserted on a delivery system into the device; the coronary stent is then manually manoeuvred on the delivery system to the injured site of the coronary artery, the delivery system is locked in the device, and the stent is positioned in the coronary artery using the rotation wheel. A second embodiment of the device consists of a body with a tail portion, a wheel for rotating a screw, a screw, rotating gears, a clamping cylinder, and a lock button with springs for accommodating guides for a deliverysystem inside the body. When preparing the device for use, the coronary stent is first inserted on a delivery system into the device; the coronary stent is then manually manoeuvred on the delivery system to the injured site of the coronary artery, the delivery system is locked in the device, and the stent is positioned in the coronary artery using the rotation wheel.
Owner:SEVEN SONS LTD R N 515985570 THECO

Novel galactoside inhibitors of galectin

The present invention relates to D-galactopyranose compounds of formula (1) wherein the pyranose ring is beta-D-galactopyranose, these compounds are high affinity galectin-1 and / or-3 inhibitors for use in the treatment of inflammation; thrombosis caused by inflammation; specific dermatitis; acute coronary syndrome; fibrosis, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, ocular fibrosis, and fibrosis of the skin and heart; local fibrosis, such as Duput's foot disease and Petroleum disease; fibrosis complications of other therapies such as coronary artery stents, bile duct stents, cerebral artery stents and ureteral stents; scleroderma; scars; scar tumor formation; new coronal pneumonia-19; acute lung injury; an ARDS; viral pneumonia; abnormal scar formation; surgical adhesion; infectious shock; cancers such as colorectal cancer, other gastrointestinal cancers such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancer, mesothelioma, female cancers such as breast cancer, ovarian cancer, uterine cancer, cervical cancer, fallopian tube cancer, brain cancers such as myeloblastoma, glioma, meningioma, skeletal and muscle sarcoma and other sarcoma, leukemia and lymphoma such as T cell lymphoma; transplant rejection; metastatic cancers; aging; dementia; alzheimer's disease; bone diseases driven by TGF-beta, such as osteogenesis imperfection; pulmonary arterial hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, rheumatoid lung disease; , Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, herpes virus, coronavirus, hepatitis C; metabolic disorders; heart diseases; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, such as cancer-associated neovascularization; and ocular diseases such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistance; obesity; marfan's syndrome; a Royal's syndrome; kidney disease; diastolic heart failure; fibrotic pulmonary complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermanski-Priderac syndrome, liver diseases, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine diseases, such as uterine fibroids and uterine or cervical fibrosis.
Owner:GALECTO BIOTECH

A method of processing cobalt-base alloy superfine thin-walled tubes for stents

The invention relates to a forming technology of superfine thin walled tubular products for vessel stents in the field of treatment, specifically to a method of processing cobalt-base alloy superfine thin walled tubes for novel coronary artery stents. The method solves the problems of great difficulty in tubular product processing and low yield of tubular products in a conventional technology. The method for forming finished products comprises the successive technological processes of smelting, forging, hot rolling, hot rolling punching, honing and cleaning of inner surfaces and outer surfaces, annealing, cold rolling / drawing, annealing, and repeated cold rolling / drawing. During overall process of the repeated cold rolling, diameter reducing deformation of the tubular products should be controlled in each pass, and match relationship between the diameter reducing deformation and wall reducing deformation should be well adjusted for guaranteeing that load carrying capability of inner walls does not exceed sigma b (breaking strength) and thus for preventing horizontal microscopic breakage. With rough blanks of the tubular products being acquired in high temperature conditions and the cobalt-base alloy tubular products being acquired through rolling at a room temperature, the processing method guarantees high dimensional precision, bright and clean inner and outer surfaces and excellent mechanical property of the tubular products; and is easy to realize and has high controllability and high economic benefit.
Owner:JIANGSU FENGYUAN MEDICAL DEVICES CO LTD

Novel galactoside inhibitors of galectin

The present invention relates to D-galactopyranose compounds of formula (1) wherein the pyranose ring is beta-D-galactopyranose, these compounds are high affinity galectin-3 inhibitors for use in the treatment of inflammation; thrombosis caused by inflammation; specific dermatitis; acute coronary syndrome; fibrosis, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, ocular fibrosis, and fibrosis of the skin and heart; local fibrosis, such as Duput's foot disease and Petroleum disease; fibrosis complications of other therapies such as coronary artery stents, bile duct stents, cerebral artery stents and ureteral stents; scleroderma; scars; scar tumor formation; new coronal pneumonia-19; acute lung injury; an ARDS; viral pneumonia; abnormal scar formation; surgical adhesion; infectious shock; cancers such as colorectal cancer, other gastrointestinal cancers such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancer, mesothelioma, female cancers such as breast cancer, ovarian cancer, uterine cancer, cervical cancer, fallopian tube cancer, brain cancers such as myeloblastoma, glioma, meningioma, skeletal and muscle sarcoma and other sarcoma, leukemia and lymphoma such as T cell lymphoma; transplant rejection; metastatic cancers; aging; dementia; alzheimer's disease; bone diseases driven by TGF-beta, such as osteogenesis imperfection; pulmonary arterial hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, rheumatoid lung disease; , Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, herpes virus, coronavirus, hepatitis C; metabolic disorders; heart diseases; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, such as neovascularization associated with cancer; and ocular diseases such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistance; obesity; marfan's syndrome; a Royal's syndrome; kidney disease; diastolic heart failure; fibrotic pulmonary complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermanski-Priderac syndrome, liver diseases, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine diseases, such as uterine fibroids and uterine or cervical fibrosis.
Owner:GALECTO BIOTECH

Extension catheter for coronary artery stent implantation operation

The invention relates to an extension catheter for coronary stent implantation operation. The extension catheter comprises a catheter and a guide wire, wherein the catheter is connected with the guide wire, the catheter comprises a catheter head end, a catheter body and a catheter tail end, one end of the catheter body is connected with the catheter head end, the other end of the catheter body is connected with the catheter tail end, and the surface of the catheter body is provided with micropore structures. When the extension catheter enters a narrow section of a blood vessel to cause blood vessel blockage, the micropore structures can enable blood to circulate, and pain and uncomfortable symptoms of a patient are relieved; the micropore structures are elliptical, so that the scratch to the blood vessel can be reduced, and the injury to patients can be reduced; the position, 3-5 centimeters away from the guide wire, of the catheter is not provided with the micropore structures, and smooth conveying of the extension catheter can be guaranteed; a head hose is arranged, the smooth head can enable the operation process to be safer, the probability of scratching the blood vessel is reduced, and the occurrence of vascular complications is reduced; and the condition of the catheter can be clearly observed through X-ray fluoroscopy in the radiography process through a marking belt, and therefore, the operation can be conveniently performed.
Owner:LIANYUNGANG FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products